Michelle Hastings

Michelle Hastings is a distinguished academic leader and researcher serving as the Pfizer Upjohn Endowed Professor of Pharmacology and Director of RNA Therapeutics at the University of Michigan Medical School. Based in Ann Arbor, Michigan, she is an NIH-funded scientist whose work focuses on uncovering the molecular mechanisms underlying human disease. Her research integrates cutting-edge molecular biology with translational applications, positioning her at the forefront of RNA-based therapeutic innovation.

Dr. Hastings leads a highly regarded research program dedicated to understanding and correcting molecular dysfunctions associated with a wide range of genetic and neurodegenerative disorders, including Usher syndrome, Batten disease, cystic fibrosis, spinal muscular atrophy, Parkinson’s disease, and Alzheimer’s disease. Through her leadership, the Hastings Lab explores RNA-targeted approaches—particularly antisense oligonucleotide (ASO) therapies—to develop precision treatments for these complex conditions. Her work has contributed to advancing personalized medicine and expanding the therapeutic potential of RNA technologies.

Prior to joining the University of Michigan, Dr. Hastings held tenured faculty and leadership roles at Rosalind Franklin University of Medicine and Science, where she also directed the Center for Genetic Diseases. In addition to her academic responsibilities, she serves on scientific advisory boards for biotechnology companies, helping guide the development of innovative therapeutics. Widely published and recognized for her contributions to molecular biology and genetic medicine, Dr. Hastings continues to play a pivotal role in shaping the future of RNA therapeutics and rare disease research.

• St. Olaf College - BA, Biology
• Marquette University - Ph.D., Molecular Biology